Stephen Zaniboni

selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Their most advanced drug candidate is si-544 which is a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.The company is well positioned to expand its range of class-leading ion channelblockers by targeting additional potassium, sodium, calcium and chloride channels, which will lead to other clinical applications in pain management and oncology.